Señales en vivo de ALNOX.PA | Maximiza tus Ganancias con Getagraph.com

Live Chart Being Loaded With Signals

Commentary (31 dic 1970 @ 19:00):

NOXXON Pharma N.V., a clinical-stage biopharmaceutical company, focuses on the development of proprietary therapeutics for the treatment of cancer in Germany...

Stats
Volumen de hoy	10.21M
Volumen promedio	4.35M
Capitalización de mercado	0.00
Last Dividend	€0 ( N/A )
Next Dividend	€0 ( N/A )
P/E	-0.187
ATR14	€0 (0.00%)

NOXXON Pharma NV Correlación

10 Correlaciones Más Positivas

10 Correlaciones Más Negativas

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

NOXXON Pharma NV Finanzas

Annual	2021
Ingresos:	€0.00
Beneficio Bruto:	€0.00 (0.00 %)
EPS:	€-45.99

FY	2021
Ingresos:	€0.00
Beneficio Bruto:	€0.00 (0.00 %)
EPS:	€-45.99

FY	2020
Ingresos:	€0.00
Beneficio Bruto:	€0.00 (0.00 %)
EPS:	€-32.16

FY	2019
Ingresos:	€0.00
Beneficio Bruto:	€-1.03M (0.00 %)
EPS:	€-7.72

Financial Reports:

No articles found.

NOXXON Pharma NV

NOXXON Pharma N.V., a clinical-stage biopharmaceutical company, focuses on the development of proprietary therapeutics for the treatment of cancer in Germany. Its Spiegelmer platform has a proprietary pipeline of clinical-stage product candidates, including its lead cancer drug candidate, NOX-A12, which is under development as a combination therapy for various cancer indications, such as metastatic pancreatic and colorectal cancer, glioblastoma, myeloma, and chronic lymphocytic leukemia. It is also developing NOX-E36, which has completed Phase 1/2 clinical trial for the treatment of diabetic nephropathy. The company has a collaboration agreement with Merck & Co. Inc. to study NOX-A12 combined with Keytruda/pembrolizumab inhibitor antibody in patients with metastatic solid tumors. NOXXON Pharma N.V. was founded in 1997 and is based in Berlin, Germany.